Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Base Catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN114249690A reveals a novel DBU-catalyzed route for Roxadustat. Achieve high purity and reduced manufacturing costs with our scalable pharmaceutical intermediate solutions.
Patent CN111454222B reveals a metal-free CO2 fixation route for quinazolinediones. This method offers high yields, mild conditions, and significant cost reduction potential.
Patent CN111909038A introduces a safe, low-pressure Schiff base catalyzed route for phenylenediamine, offering significant cost and safety advantages over traditional nitration.
Patent CN114522738B enables efficient 1,3-propanediol synthesis via Cu-catalysis. Delivers supply chain stability and cost reduction in polymer intermediate manufacturing.
Patent CN103087039A details a novel room-temperature synthesis of poly-substituted benzo[1,3]dioxolanes using ethyl 4-chloroacetoacetate and 1,2-allenones, offering significant cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN104817484A reveals metal-free 2-indolone synthesis. Offers cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN118834244B reveals advanced palladium complex enhancing Suzuki coupling efficiency. Offers supply chain stability and reduced purification costs for pharmaceutical manufacturers.
Patent CN111690009A discloses novel Co/Fe complexes for high-ee hydrogenation of alpha-silyl styrenes, offering cost-effective pharma intermediate synthesis.
Patent CN110003299A details a novel THF-based synthesis for Betamethasone intermediates offering higher purity and reduced toxicity for reliable pharmaceutical supply chains.
Patent CN105622537A details a Lewis base-catalyzed route for isoxazoles, offering cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN105622537A reveals a metal-free synthesis for 3,4,5-trisubstituted isoxazoles. Discover cost-effective, scalable pharmaceutical intermediate manufacturing solutions.
Patent CN106674178A reveals a metal-free DBU-catalyzed route for chromans, offering high yields and reduced environmental impact for reliable pharmaceutical intermediate suppliers.
Patent CN105622537A enables eco-friendly production of high-purity isoxazole intermediates through Lewis base catalysis with mild conditions and consistent yields above 90%, ensuring cost reduction and reliable supply for pharmaceutical manufacturing.
Breakthrough chiral copper-based catalyst enables high-yield asymmetric synthesis of optically active indole compounds with >91% ee, enhancing pharmaceutical intermediate production efficiency.
Patent CN118930570B enables room-temperature synthesis of isoindolinone derivatives with high yield and purity delivering significant cost reduction supply chain reliability
Discover how novel biphenyl-type tridentate ligand ruthenium complexes enable ester-to-alcohol hydrogenation at 60-100°C and 3-10MPa, reducing costs and safety risks for pharma production.
Solve 4-arylbutyronitrile synthesis challenges with 100% atom economy, room-temperature visible light iron catalysis. Eliminate noble metals, reduce waste. Scale to 100MT/yr.
Solve imidazo[1,2-a]pyridine amine synthesis challenges with 90%+ yields. Reduce steps, costs, and supply chain risks. Contact for CDMO solutions.
Solve ibrutinib impurity issues with mixed base method: 90% yield, no flocs, 0.1% single impurity. Scale to 100MT/yr with NINGBO INNO PHARMCHEM.
Solve isoquinolinone synthesis challenges with 92%+ yields, oxygen-based oxidation, and 5-step routes. Reduce costs and supply risks for pharma intermediates.